ANTRODIA CAMPHORATA AND GANODERMA LUCIDUM COMPOSITION HAVING FUNCTIONALITY TO INHIBIT RENAL CANCER CELL GROWTH AND ENHANCE KIDNEY FUNCTIONMPOSITION

Abstract

The present invention provides an Antrodia camphorata and Ganoderma lucidum composition having functionality to inhibit renal cancer cell growth and enhance kidney function. This navel composition is constituted of water-soluble base material, plasticity-increasing base material, Antrodia camphorata extract, Ganoderma lucidum extract, and auxiliary enzyme. Differing from the conventional therapeutics treating the glomerulonephritis by administering high-dosage steroid for 1-4 months, the renal function of a patient suffering with serious kidney failure can be obviously enhanced after administering low-dosage Antrodia camphorata and Ganoderma lucidum composition of 7 mg/day/kg to the patient for 20 days. Moreover, because the cell biological experiments have proved that the Antrodia camphorata and Ganoderma lucidum composition of the present invention possess the functionality to inhibit renal cancer cell growth, this novel composition can indeed be used with chemotherapy drugs clinically, so as to solve the issue that the chemotherapy drugs cannot effectively inhibit the renal cancer cell growth.

Claims

1. An Antrodia camphorata and Ganoderma lucidum composition having functionality to inhibit renal cancer cell growth and enhance kidney function, comprising: a first substrate, having a first weight percent in a range from 40 wt % to 60 wt %; a second substrate, having a second weight percent in a range from 5 wt % to 10 wt %; an Antrodia camphorata extract, having a third weight percent in a range from 8 wt % to 15.5 wt %; a Ganoderma lucidum extract, having a fourth weight percent in a range from 18 wt % to 34 wt %; and a first coenzyme, having a fifth weight percent in a range from 1.5 wt % to 3.1 wt %; and wherein after administering the Antrodia camphorata and Ganoderma lucidum composition with an adult dosage of at least 3 mg/day/kg, the cell viability of kidney cancer cells is reduced an below 30%; wherein a daily dosage of the Antrodia camphorata and Ganoderma lucidum composition for a renal failure patient to regulate blood urea nitrogen (BUN) and creatinine (Cr) is at least 3 mg/day/kg.

2. The Antrodia camphorata and Ganoderma lucidum composition of claim 1, wherein the kidney cancer cell is human embryonic kidney cell 293T (HEK293T cell).

3. The Antrodia camphorata and Ganoderma lucidum composition of claim 1, wherein the Antrodia camphorata and Ganoderma lucidum composition can be processed to a dripping pill with a specific pill size and a specific pill weight; wherein the specific pill size is in a range from 2.0 mm to 3.5 mm and the specific pill weight is in a range from 18 mg/pill to 25 mg/pill.

4. The Antrodia camphorata and Ganoderma lucidum composition of claim 1, further comprising a second coenzyme, having a sixth weight percent in a range from 1.5 wt % to 3.1 wt %.

5. The Antrodia camphorata and Ganoderma lucidum composition of claim 1, wherein the first substrate is a water-soluble base material selected from the group consisting of: polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), polyoxyethylene monostearate (S40), sodium stearate, glycerin, gelatin, urea, poloxamer, and combination of the aforesaid two or more materials.

6. The Antrodia camphorata and Ganoderma lucidum composition of claim 1, wherein the first substrate is composed of a polyethylene glycol (PEG) and a sodium stearate by a ratio of 9:1.

7. The Antrodia camphorata and Ganoderma lucidum composition of claim 1, wherein the second substrate is a plasticity-increasing base material selected from the group consisting of: pre-gelatinized starch, carboxymethyl starch, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, acacia, alginic acid, dextrin, cyclodextrin, agar, lactose, and combination of the aforesaid two or more materials.

8. The Antrodia camphorata and Ganoderma lucidum composition of claim 1, wherein the Antrodia camphorata extract at least comprises triterpenoids and adenosine.

9. The Antrodia camphorata and Ganoderma lucidum composition of claim 1, wherein the Ganoderma lucidum extract at least comprises polysaccharides.

10. The Antrodia camphorata and Ganoderma lucidum composition of claim 4, wherein both the first coenzyme and the second coenzyme are a B vitamin group or a ubiquinone.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The invention as well as a preferred mode of use and advantages thereof will be best understood by referring to the following detailed description of an illustrative embodiment in conjunction with the accompanying drawings, wherein:

[0023] FIG. 1 shows two plot curves of dosage versus cell viability;

[0024] FIG. 2 shows two plot curve of dosage versus cell viability.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] To more clearly describe an Antrodia camphorata and Ganoderma lucidum composition having functionality to inhibit renal cancer cell growth and enhance kidney function according to the present invention, embodiments of the present invention will be described in detail with reference to the attached drawings hereinafter.

[0026] This Antrodia camphorata and Ganoderma lucidum composition is fabricated through a solid dispersion process consisting of following processing steps: [0027] step (1): mixing a water-soluble base material with a plasticity-increasing base material for obtaining a mixed base material, and then heating the mixed base material for further obtaining a melted substrate; [0028] step (2): adding an Antrodia camphorata extract, a Ganoderma lucidum extract, and a first coenzyme into the melted substrate so as to obtain a fluid mixture; [0029] step (3): evenly stirring the fluid mixture, and then transferring the fluid mixture to a reservoir bottle, so as to store the fluid mixture under 70-100° C.; [0030] step (4): using a pill dropping machine to drop the fluid mixture into a condensing agent under 70-100° C., so as to make the dropped fluid mixture become a dripping pill in the condensing agent; and [0031] step (5): collecting a variety of dripping pills.

[0032] The collected dripping pills have a dripping pill with a specific pill size and a specific pill weight, wherein the specific pill size is in a range from 2.0 mm to 3.5 mm and the specific pill weight is in a range from 18 mg/pill to 25 mg/pill. Moreover, it needs to further explain that, the water-soluble base material used in the step (1) can be a polyethylene glycol (PEG), a polyvinylpyrrolidone (PVP), polyoxyethylene monostearate (S40), a sodium stearate, a glycerin, a gelatin, a urea, poloxamer, or a combination of the aforesaid two or more materials. In addition, the plasticity-increasing base material used in the step (1) can be a pre-gelatinized starch, a carboxymethyl starch, a methylcellulose, a sodium carboxymethyl cellulose, a hydroxypropyl methylcellulose, a acacia, a alginic acid, a dextrin, a cyclodextrin, an agar, a lactose, or a combination of the aforesaid two or more materials.

[0033] Moreover, the Antrodia camphorata extract used in the step (1) has a third weight percent in a range from 8 wt % to 15.5 wt %, and at least comprises compositions of triterpenoids and adenosine. On the other hand, the Ganoderma lucidum extract used in the step (1) has a third weight percent in a range from 18 wt % to 34 wt %, and at least comprises compositions of polysaccharides. Furthermore, the first coenzyme can be a B vitamin group or a ubiquinone, and has a fifth weight percent in a range from 1.5 wt % to 3.1 wt %.

[0034] Now referring to following Table 1, which records with the functional compositions of the collected dripping pill of the Antrodia camphorata and Ganoderma lucidum composition.

TABLE-US-00001 TABLE 1 Ingredients Pharmacological effects Triterpenoids inhibiting the release of histamine, stimulating liver functions, and anti-inflammation Adenosine inhibiting the aggregation of platelet and improving blood circulation Polysaccharides immune modulation and anti-allergy B vitamin group dissipating fatigue

[0035] It is able to further add a second coenzyme into the fluid mixture during the step (2), so as to enhance or increase the pharmacological effects of the dripping pill of the Antrodia camphorata and Ganoderma lucidum composition. In which, the second coenzyme can be a B vitamin group or a ubiquinone, and has a fifth weight percent in a range from 1.5 wt % to 3.1 wt %. Moreover, it is well know that the ubiquinone includes the pharmacological effects of: strengthening immunity and antioxidant capacity, slowing aging, and enhancing human vitality. So that, since the dripping pill of the Antrodia camphorata and Ganoderma lucidum composition includes many pharmacological effects, the dripping pill can provides health benefits to users' cardiovascular system and renal function.

Preferred Embodiment

[0036] A preferred embodiment is deigned and provided for verifying the medical efficacies and pharmacological effects of the Antrodia camphorata and Ganoderma lucidum composition in following paragraphs, wherein the constituting ingredients of the preferred embodiment of the Antrodia camphorata and Ganoderma lucidum composition is listed in following Table 2.

TABLE-US-00002 TABLE 2 Ingredients Formula water-soluble 45 wt % polyethylene glycol + base material 5 wt % sodium stearate plasticity-increasing 5 wt % hydroxypropyl methylcellulose base material Antrodia camphorata 12.5 wt % extract Ganoderma lucidum 27.5 wt % extract B vitamin group  2.5 wt % coenzyme Q10  2.5 wt %

[0037] The Antrodia camphorata and Ganoderma lucidum composition is processed to a dripping pill with a grain size of 3.0 mm. Moreover, inventors of the present invention use the Antrodia camphorata and Ganoderma lucidum composition with a daily dosage of at least 3 mg/day/kg to finish a clinical trial. The object in the clinical trial is a bladder cancer patient simultaneously suffering with renal failure. The patient has been unable to urinate easily and normally since being admitted to hospital in July, 2015. Following Table 3 has recorded with blood urea nitrogen (BUN) and creatinine (Cr) data of the patient.

TABLE-US-00003 TABLE 3 Test item BUN Cr (mg/dl) (mg/dl) Date normal level: 7-20 mg/dl normal level: 0.6-1.2 mg/dl 2015 Jul. 22 89.5 5.1 2015 Aug. 3 90.7 5.5 2015 Aug. 24 149.5 4.9 2015 Aug. 8 106.5 3.5 2015 Sep. 4 100.8 2.6

[0038] As medically personnel knows, renal failure would cause the patient suffering from oliguria (defined as a urine output that is less than 400 mL daily in adults). Moreover, because the wastes in the body of the renal failure patient is difficult to be excreted, the renal failure patient may also suffer from some complications, such as acidosis, hyperkalemia, hypocalcemia, hyperphosphatemia, and anemia. The value of glomerular filtration rate (GFR) is generally used for judging whether an adult suffers from renal failure or not, wherein the GFR can be measured through the change of urine volume and the waste concentration in blood. Therefore, from above-presented Table 3, it can find that the renal failure of the inpatient does not be improve although the patient has been undergone the immunotherapy treatment for 2 months.

[0039] So that, attending doctor starts to administer the Antrodia camphorata and Ganoderma lucidum composition with a daily dosage of 7 mg/day/kg to the patient from September, 2015. Therefore, the renal failure patient is able to urinate after receiving such treatment for 20 days. Following Table 4 has recorded with BUN and Cr data of the renal failure patient.

TABLE-US-00004 TABLE 4 Test item BUN Cr (mg/dl) (mg/dl) Date normal level: 7-20 mg/dl normal level: 0.6-1.2 mg/dl 2015 Sep. 24 30.6 1.7 2015 Oct. 8 52.0 1.5 2015 Nov. 19 39.3 1.7

[0040] Comparing to the BUN (100.8 mg/dl) and Cr (2.6 mg/dl) data measured on Sep. 4, 2015, the BUN and Cr level of the renal failure patient are respectively lowered to 30.6 mg/dl and 1.7 mg/dl after administering the Antrodia camphorata and Ganoderma lucidum composition with 7 mg/day/kg daily dosage to the patient for 20 days. That is, the clinical trial data have proved that the Antrodia camphorata and Ganoderma lucidum composition proposed by the present invention indeed can enhance kidney function.

[0041] Furthermore, in order to verify whether the Antrodia camphorata and Ganoderma lucidum composition possesses the functionality to inhibit renal cancer cell growth or not, the inventors of the present invention has completed a cell biological experiment. The cell biological experiment includes a control (Col) group and an experiment (Exp) group.

[0042] In the group Col, human embryonic kidney cells 293T (HEK293T cells) are placed into a 96-well microplate for making the 96-well microplate carries with 1×10.sup.4 cell/well HEK293T cells. Moreover, the HEK293T cells in the 96-well microplate are treated with water for 24 hours and 48 hours, respectively.

[0043] In the group Exp, human embryonic kidney cells 293T (HEK293T cells) are placed into a 96-well microplate for making the 96-well microplate carries with 1×10.sup.4 cell/well HEK293T cells. Particularly, the HEK293T cells in the 96-well microplate are treated with a solution of Antrodia camphorata and Ganoderma lucidum composition for 24 hours and 48 hours, respectively. Moreover, the volume of the solution is at least 1.5 mg/mL, and an adult dosage of the Antrodia camphorata and Ganoderma lucidum composition in the solution is 3 mg/day/kg.

[0044] Please refer to FIG. 1, which illustrates two plot curves of dosage versus cell viability. Moreover, please simultaneously refer to FIG. 2, where two plot curves of dosage versus cell viability are provided. From the experimental data shown in FIG. 1 and FIG. 2, it can easily find that, after using the Antrodia camphorata and Ganoderma lucidum composition with different dosages to treat the HEK293T cells, the Antrodia camphorata and Ganoderma lucidum composition of at least 1.5 mg/mL is effectively inhibit the growth of HEK293T cell; moreover, the cell viability of the HEK293T cells is reduced to below 30% (15-30%). So that, the experimental data of FIG. 1 and FIG. 2 have proved that the Antrodia camphorata and Ganoderma lucidum composition proposed by the present invention indeed possesses the functionality to inhibit renal cancer cell growth.

[0045] Therefore, through above descriptions, the Antrodia camphorata and Ganoderma lucidum composition for inhibiting renal cancer cell growth and enhancing kidney function provided by the present invention has been introduced completely and clearly; in summary, the present invention includes the advantages of:

[0046] (1) Differing from the conventional therapeutics treating the glomerulonephritis by administering high-dosage steroid for 1-4 months, the renal function of a patient suffering with serious kidney failure can be obviously enhanced after administering low-dosage Antrodia camphorata and Ganoderma lucidum composition of 7 mg/day/kg to the patient for 20 days.

[0047] (2) Moreover, because the cell biological experiments have proved that the Antrodia camphorata and Ganoderma lucidum composition of the present invention possess the functionality to inhibit renal cancer cell growth, this novel composition can indeed be used with chemotherapy drugs clinically, so as to solve the issue that the chemotherapy drugs cannot effectively inhibit the renal cancer cell growth.

[0048] The above description is made on embodiments of the present invention. However, the embodiments are not intended to limit scope of the present invention, and all equivalent implementations or alterations within the spirit of the present invention still fall within the scope of the present invention.